Redefining GPCR Drug Discovery
Our Mission
We aim to discover and develop medicines that matter. We are driven by one goal: to improve lives by advancing innovative treatments that address real, unmet medical needs, for the patients who need them most. Every decision we make begins and ends with the patients.
Our Mission
We aim to discover and develop medicines that matter. We are driven by one goal: to improve lives by advancing innovative treatments that address real, unmet medical needs, for the patients who need them most. Every decision we make begins and ends with the patients.
Data-Driven AI-Powered Drug Discovery
Based in the Bay Area in California, Sevena is at the forefront of drug discovery, integrating cutting-edge AI technology with deep expertise in GPCR biology to unlock novel therapeutics for obesity and oncology. By combining AI-driven insights with unparalleled GPCR know-how, Sevena aims to target previously undruggable GPCRs, accelerating the development of breakthrough treatments.
We leverage a foundational AI/ML model, powered by proprietary pharmaceutical data from over 30 GPCR programs.
This unique integration allows us to rapidly validate and develop novel GPCR antagonists with precision, offering fast, high-quality feedback at every stage.
We have access to over 650 proprietary HTS-ready stable clones and assay protocols, ensuring comprehensive coverage of all druggable GPCRs, which speeds up the discovery process and enables advanced screening in biologically relevant contexts.
